Serum Peptide Immunoglobulin G Autoantibody Response in Patients with Different Central Nervous System Inflammatory Demyelinating Disorders
Hye Lim Lee(Korea University Medical Center), Byoung Joon Kim(Samsung Medical Center), Mi Young Jeon(Samsung Medical Center), Sang‐Soo Lee(Hallym University), Ha Young Shin(Yonsei University), Jin Myoung Seok(Samsung Medical Center), Byung‐Jo Kim(Korea University), Sa‐Yoon Kang(Jeju National University), Young‐Min Lim(Ulsan College), Hung Youl Seok(Keimyung University), Jin‐Woo Park(Korea University), Ho‐Jin Kim(National Cancer Center), Sung-Hyun Lee(Chungbuk National University), Ju‐Hong Min(Samsung Medical Center), Oh-Hyun Kwon(Eulji University)
Cited by 5
Related Papers
Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder
|Multiple Sclerosis Journal|2011|284
A New Subtype Classification of Ischemic Stroke Based on Treatment and Etiologic Mechanism
|European Neurology|2006|121
The novel strategies for next-generation cancer treatment: miRNA combined with chemotherapeutic agents for the treatment of cancer
|Oncotarget|2018|104
The usefulness of brain MRI at onset in the differentiation of multiple sclerosis and seropositive neuromyelitis optica spectrum disorders
|Multiple Sclerosis Journal|2013|84
Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: A multicenter retrospective study in Korea
|Multiple Sclerosis Journal|2017|82